The late-stage chronic kidney disease (CKD) drugs market is witnessing substantial growth as the prevalence of CKD rises globally. According to The Insight Partners, the market, valued at approximately USD 5.74 billion in 2021, is expected to reach USD 17.95 billion by 2031, reflecting a CAGR of 12.2%. This expansion is driven by rising healthcare demand, supportive reimbursement policies, and...